These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17673612)

  • 1. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
    Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID
    Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
    Scagliotti GV
    Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of pemetrexed.
    Sørensen JB
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):919-28. PubMed ID: 21599552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
    Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical pharmacology of pemetrexed.
    Calvert AH
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
    Wang Y; Zhao R; Chattopadhyay S; Goldman ID
    Cancer Res; 2002 Nov; 62(22):6434-7. PubMed ID: 12438230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed disodium.
    Gibbs D; Jackman A
    Nat Rev Drug Discov; 2005 May; Suppl():S16-7. PubMed ID: 15962527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
    Li KM; Rivory LP; Clarke SJ
    Br J Cancer; 2007 Oct; 97(8):1071-6. PubMed ID: 17912246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.
    Tanaka H; Horiike A; Sakatani T; Saito R; Yanagitani N; Kudo K; Ohyanagi F; Horai T; Nishio M
    Anticancer Drugs; 2015 Jun; 26(5):573-8. PubMed ID: 25714250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.
    Min SH; Goldman ID; Zhao R
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):819-27. PubMed ID: 17594092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.